share_log

中國生物製藥：自願公告 - 「碘普羅胺注射液」獲批上市

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "IOPROMIDE INJECTION"

香港交易所 ·  Mar 24 18:11
Summary by Moomoo AI
中國生物製藥有限公司宣佈，旗下開發的碘普羅胺注射液（商標名：多碘）已於2024年3月25日獲得中國國家藥品監督管理局的上市批准。該產品為非離子型水溶性X-射線造影劑，用於血管內和體腔內造影，具有高含碘量和優良造影效果。碘普羅胺的上市將滿足中國日益增長的造影劑市場需求，並為臨床醫學影像提供更多選擇。中國生物製藥表示，除多碘外，公司還有其他造影劑產品已獲批上市，並有多款在研造影劑，預期將進一步鞏固其在醫學影像領域的市場地位。
中國生物製藥有限公司宣佈，旗下開發的碘普羅胺注射液（商標名：多碘）已於2024年3月25日獲得中國國家藥品監督管理局的上市批准。該產品為非離子型水溶性X-射線造影劑，用於血管內和體腔內造影，具有高含碘量和優良造影效果。碘普羅胺的上市將滿足中國日益增長的造影劑市場需求，並為臨床醫學影像提供更多選擇。中國生物製藥表示，除多碘外，公司還有其他造影劑產品已獲批上市，並有多款在研造影劑，預期將進一步鞏固其在醫學影像領域的市場地位。
CHINA BIOPHARMACEUTICAL CO., LTD. ANNOUNCED THAT ITS SUBSIDIARY-DEVELOPED IODOPROAMINE INJECTION (TRADEMARK: POLYIODINE) WAS APPROVED FOR LISTING BY CHINA'S NATIONAL DRUG ADMINISTRATION ON MARCH 25, 2024. The product is a non-ionic water-soluble X-ray imaging agent for intravascular and intra-abdominal imaging, with a high iodine content and excellent imaging effect. The listing of iodiproamine will meet the growing demand of the imaging agent market in China and provide more options for clinical medical imaging. China Biopharmaceuticals said that in addition to iodide, the company also has other imaging products that have been approved and that several imaging agents are in development, which is expected to further consolidate its market position in the field of medical imaging.
CHINA BIOPHARMACEUTICAL CO., LTD. ANNOUNCED THAT ITS SUBSIDIARY-DEVELOPED IODOPROAMINE INJECTION (TRADEMARK: POLYIODINE) WAS APPROVED FOR LISTING BY CHINA'S NATIONAL DRUG ADMINISTRATION ON MARCH 25, 2024. The product is a non-ionic water-soluble X-ray imaging agent for intravascular and intra-abdominal imaging, with a high iodine content and excellent imaging effect. The listing of iodiproamine will meet the growing demand of the imaging agent market in China and provide more options for clinical medical imaging. China Biopharmaceuticals said that in addition to iodide, the company also has other imaging products that have been approved and that several imaging agents are in development, which is expected to further consolidate its market position in the field of medical imaging.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more